PolyPid (PYPD) Stock Price, News & Analysis

Company Overview

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia. OncoTears has received marketing authorization in select countries of the former CIS, and the company is advancing regulatory filings for its lead assets in the United States and European Union. Research and clinical operations are conducted in Israel, with strategic collaborations established to support commercialization efforts and late‐stage clinical trials in multiple geographies.

Under the leadership of co-founder and Chief Executive Officer Yoel Hakim, PolyPid’s management team brings together expertise in polymer chemistry, pharmacology and regulatory affairs. As a Nasdaq‐listed entity, the company remains focused on driving its clinical programs toward pivotal studies, while exploring new therapeutic applications of its mucus‐penetrating delivery platform to address unmet medical needs across a range of mucosal diseases.

Key Stats

• Today's Range: $4.70 to $5.08
• 50-Day Range: $3.74 to $5.58
• 52-Week Range: $3.06 to $5.73
• Volume: 156,784 shs
• Average Volume: 195,400 shs
• Market Capitalization: $95.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.33
• Consensus Rating: Moderate Buy

PolyPid Stock Analysis - MarketRank™

PolyPid scored higher than 47% of companies evaluated by MarketBeat, and ranked 472nd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PolyPid has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PolyPid has a consensus price target of $11.33, representing about 126.2% upside from its current price of $5.01.

Amount of Analyst Coverage

PolyPid has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for PolyPid are expected to decrease in the coming year, from ($0.92) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PolyPid is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PolyPid is -3.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PolyPid has a P/B Ratio of 17.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.87% of the float of PolyPid has been sold short.

Short Interest Ratio / Days to Cover

PolyPid has a short interest ratio ("days to cover") of 1.06, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PolyPid has recently increased by 45.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PolyPid does not currently pay a dividend.

Dividend Growth

PolyPid does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.22

News Sentiment

PolyPid has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for PolyPid this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for PYPD on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added PolyPid to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PolyPid insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

26.47% of the stock of PolyPid is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PYPD
• CIK: 1611842
• Web: www.polypid.com
• Phone: 972-74-719-5700
• Fax: N/A
• Employees: 80
• Year Founded: 2008

Price Target and Rating

• Average Price Target for PolyPid: $11.33
• High Price Target: $13.00
• Low Price Target: $9.00
• Potential Upside/Downside: +126.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -311.08%
• Return on Assets: -150.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.35
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 17.89

Miscellaneous

• Outstanding Shares: 19,080,000
• Free Float: 14,369,000
• Market Cap: $95.59 million
• Optionable: No Data
• Beta: 1.41